Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Antithrombotic Therapy Poster III

Monday, December 8, 2008: 5:30 PM-7:30 PM
Hall A (Moscone Center)
Prospective Evaluation of An Argatroban Dosing Nomogram Using the Ecarin Chromogenic Assay at a Tertiary Institution

Cathryn Sibbald, BScPhm1*, Jin-Hyeun Huh, BScPhm, ACPR, BCPS2*, William Brien, MD, FRCPC3, Bassem Hamandi, BSc, BScPhm, MSc4*, Donna Lowe, BScPhm, PharmD3*, Menaka Pai, MD5, Anne Mcleod, MD, FRCPC6, Gary Wong, BScPhm7*, Erik Yeo, MD8 and David Barth, MD, FRCPC4*

1Pharmacy, University Health Network, University of Toronto, Toronto, ON, Canada
2Pharmacy, University Health Network, University of Toronto
3University Health Network, Toronto, ON, Canada
4University Health Network, University of Toronto
5Division of Medical Oncology/Hematology, McMaster University, Hamilton, Canada
6The University Health Network, ON, Canada
7Pharmacy, University Health Network, ON, Canada
8The University Health Network, Toronto, ON, Canada

A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens

Michele Cavo, MD1*, Antonio Palumbo, M.D.2*, Sara Bringhen, M.D.2*, Antonietta Falcone, M.D.3*, Pellegrino Musto, M.D.3*, Fabio Ciceri, M.D.3*, Mariella Grasso, M.D.3*, Renato Zambello, M.D.3*, Maria Concetta Petti, M.D.3*, Fabrizio Ciambelli, M.D.3*, Giovanni De Sabbata, M.D.3*, Stefano Rocco, M.D.3*, Luigi Gugliotta, M.D.3*, Filippo Gherlinzoni, M.D.3*, Alfonso D'Arco, M.D.3*, Massimo Martelli, M.D.3*, Tommasina Guglielmelli, M.D.3*, Paola Tacchetti, M.D.1*, Michele Baccarani, M.D.4 and Mario Boccadoro2*

1Seragnoli Institute of Hematology and Medical Oncology, Bologna University School of Medicine, Bologna, Italy
2Division of Hematology, University of Turin, Turin, Italy
3Italian Myeloma Network GIMEMA, Italy
4Dept. Hematology and Medical Oncology, University of Bologna, Bologna, Italy

Pharmacoequivalence of Enoxaparin and Contaminated Enoxaparin

Jacqueline Kuziej1*, Walter Jeske2*, Debra Hoppensteadt3*, Evangelos Litinas3*, Elizabeth McGeehan1*, Jawed Fareed, PhD4 and Richard Kennedy1*

1Loyola University Medical Center, Maywood, IL
2Cardiovascular Institute, Loyola University Medical Center, Maywood, IL
3Pathology, Loyola University Medical Center, Maywood, IL
4Loyola Univ. Medical Ctr., Maywood, IL

Clinical Predictors of Prophylaxis Use Prior to the Onset of Acute Venous Thromboembolism in Hospitalized Patients: Swiss Venous ThromboEmbolism Registry (SWIVTER)

Nils Kucher, MD1*, David Spirk, MD2*, Christoph Kalka, MD3*, Lucia Mazzolai, MD4*, Daniel Nobel, MD5*, Martin Banyai, MD6*, Beat Frauchiger, MD7* and Henri Bounameaux, MD8*

1Cardiovascular Division, University Hospital Zurich, Zurich, Switzerland
2Medical Department, Sanofi-Aventis (Suisse) Sa, Meyrin, Switzerland
3Division of Angiology, University Hospital Bern, Bern, Switzerland
4Division of Angiology, University Hospital Lausanne, Lausanne, Switzerland
5Department of Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
6Division of Angiology, Cantonal Hospital Lucerne, Lucerne, Switzerland
7Department of Medicine, Cantonal Hospital Frauenfeld, Frauenfeld, Switzerland
8Division of Angiology and Hemostasis, University Hospital of Geneva, Geneva 14, Switzerland

Standardized Thromboprophylaxis Increases Compliance and Reduces Venous Thrombotic Events (VTE) in Hospitalized Cancer PatientsClinically Relevant Abstract

Lauren Elreda, MD1*, Reena K Vora, MD2* and Alice J. Cohen, MD3

1Hematology/Oncology, Newark Beth Israel Medical Center, Newark, NJ
2Newark Beth Israel Med. Ctr., Newark, NJ
3Hematology/Oncology, Newark Beth Israel Med. Ctr., Newark, NJ

Increased Antithrombotic and Bleeding Effects of Contaminated Heparins; Hematological Implications

Evangelos Litinas, MD1*, Walter Jeske, Ph.D.2*, Debra Hoppensteadt, Ph.D.1*, Harry Messmore, MD1*, Jeanine M. Walenga, PhD3 and Jawed Fareed, Ph.D.1

1Pathology, Loyola University Medical Center, Maywood, IL
2Cardiovascular Institute, Loyola University Medical Center, Maywood, IL
3Cardiovascular Institute, Loyola Univ. Medical Center, Maywood, IL

A Higher Prevalence of HIT Antibodies in Patients May Be Due to Contaminated Heparin

Vinod Bansal1*, Josephine Cunanan2*, Cafer Adiguzel3*, Evangelos Litinas2*, Kelly Nelson2* and Jawed Fareed2

1Nephrology, Loyola University Medical Center, Maywood, IL
2Pathology, Loyola University Medical Center, Maywood, IL
3Loyola University Medical Center, Maywood, IL

The Impact of Deep Vein Thrombosis on Outcomes in Critically Ill Patients: A Systematic Review and Meta-Analysis

Alessandra Malato1*, Wendy Lim, MD2, Sergio Siragusa, MD3, Deborah Cook4* and Mark A. Crowther, MD5

1Hematology, University of Palermo, Palermo, Italy
2McMaster University, Hamilton, ON, Canada
3Istituto di Ematologia, Policlinico Universitario di Palermo, Palermo, Italy
4Hematology, McMaster University, Hamilton, Canada
5St. Joseph's Hospital and McMaster University, Hamilton, Ontario, Canada

Patterns and Predictors of Warfarin Use in Patients with Venous Thromboembolism

Steven B Deitelzweig, MD1*, Mohamed Hussein, Ms.C.S., M.S.P.H, Ph.D.2*, Jay Lin, PhD, MBA3*, Charles Kreilick4* and David Battleman, MD2*

1Ochsner Hospital, New Orleans, LA
2Health Economics and Outcomes Research, IMS Health, Falls Church, VA
3Sanofi-Aventis, Bridgewater, NJ
4Pro Unlimited Inc., Boca Raton, FL

Study of Coagulation and Platelets Response in An Open Label Randomised Non Treatment and Active Controlled (Dalteparin, Ximelagatran and DU-176b) in 4 Groups of Elderly Healthy Subjects

Michel Meyer Samama, Prof1*, Satoshi Kunitada2*, A. Oursin1*, Francois Depasse1* and Nazneen Haque3*

1Biomnis, 94208 Ivry-sur-Seine cedex, France
2Daiichi Sankyo Pharma Development, Edison, NJ
3Daiichi Sankyo Development Ltd., Buckinghamshire SL9 0BG, United Kingdom

Natural History of Mesenteric Venous Thrombosis: A Large Multi-centre  Study

Francesco Dentali, MD1, Walter Ageno1*, Dan Witt2*, Alessandra Malato3*, Nathan Clark II2*, David Garcia, MD4, Sergio Siragusa, MD5, Kathleen McCool2*, Shannon Dyke4* and Mark A. Crowther, MD6

1Clinical Med., Insubria Univ., Varese, Varese, Italy
2Kaiser Permanente Colorado
3Hematology, University of Palermo, Palermo, Italy
4University of New Mexico, Albuquerque, NM
5Istituto di Ematologia, Policlinico Universitario di Palermo, Palermo, Italy
6St. Joseph's Hospital and McMaster University, Hamilton, Ontario, Canada

Effects of the Novel, Oral, Direct Factor Xa Inhibitor Rivaroxaban on Coagulation Assays

Meyer Michel Samama, Prof1*, Lena Le Flem2*, Celine Guinet2*, Elisabeth Perzborn3*, Jean-Luc Martinoli4* and François Depasse2*

1University Hospital, Hotel Dieu, Ivry-sur-Seine cedex, France
2Biomnis, 94208 Ivry-sur-Seine cedex, France
3Bayer Healthcare AG, Wuppertal, Germany
4Stago Diagnostica, Franconville, France

Venous Thromboembolism Recurrence after a First Episode of Provoked Venous Thrombosis Due to a Transient Risk Factor. A Systematic Review of the Literature

Alfonso Iorio1*, Esmeralda Filippucci1*, Maura Marcucci1*, Clive Kearon, MB, PhD2 and Gualtiero Palareti3*

1Internal Medicine, University of Perugia, Perugia, Italy
2Henderson Hospital, McMaster University Clinic, Hamilton, ON, Canada
3Angiologia, University of Bologna, Bologna, Italy

Presence of Residual Thromboemboli at Least Six Months after a First Episode of Symptomatic Pulmonary Embolism: DO Perfusion Scintigraphy and CT-Angiography Agree?Clinically Relevant Abstract

Francesco Dentali, MD1, Marco Donadini1*, Benilde Cosmi2*, Alessandro Squizzato1*, Silvia Bozzato3* and Walter Ageno1*

1Clinical Med., Insubria Univ., Varese, Varese, Italy
2Università di Bologna
3Insubria University

Improvement of Thrombolysis by Rivaroxaban, An Anti Xa Inhibitor. Potential Therapeutic Importance in Patients with Thrombosis

Remi Varin1*, Shasultan Mirshahi2*, Pehzman Mirshahi3*, Li Lu-Hong1*, Gerald Kierzek4*, Jean-Francois Vigneau4*, Jean-Pierre Marie5, Elisabeth Perzborn6*, Massoud Mirshahi3*, Claudine Soria1* and Jeannette Soria3*

1MERCI laboratory - Rouen university hospital, Rouen, France
2Diagnostica Stago, Genevilliers, France
3Laboratoire Onco-Hématologie Hotel Dieu et Centre de Recherches des Cordeliers UMR872, Paris, France
4Emergency Unit Hotel Dieu, Paris, France
5Hematologie et Oncologie Medicale, Hopital Hotel-Dieu, Paris, France
6Bayer Healthcare AG, Bayer Healthcare AG, Wuppertal, Germany

Case Fatality Rates of Recurrent Venous Thromboembolism during and Following Anticoagulation TherapyClinically Relevant Abstract

Marc Carrier, MD, Gregoire Le Gal, MD, PhD*, Philip Wells, MD, MSc* and Marc Rodger, MD, MSc*

University of Ottawa, Ottawa, ON, Canada

Validation of Pharmacokinetic {PK} Simulation for Fondaparinux (FPX) Dosing by FPX-Specific Anti-Factor Xa Assay in Elderly Cancer Patients with Severe Renal Dysfunction

Chin Y Liu, PharmD1* and Judith C. Andersen, MD2

1Pharmacy, Karmanos Cancer Institute, Detroit, MI
2Wayne State University, Karmanos Cancer Institute, Detroit, MI

Surveillance Study of Temporary IVC Filters placed in Patients with VTE and Contraindications for Full Dose Anticoagulant Therapy

Angel G. Galvez, MD, PhD1, Benjamin Parsons, D.O.2*, Daniel Resnick, M.D.3*, Morawa Ewelina, M.D.2*, Abhilasha Radharkrishnan, M.D.2*, Matthew Jimenez, M.D.4* and Richard Messersmith, M.D.5*

1Oncology Specialists, Park Ridge, IL
2Internal Medicine, Lutheran General Hospital, Park Ridge, IL
3Surgery, Lutheran General Hospital, Park Ridge, IL
4Orthopedic surgery, Lutheran General Hospital, Park Ridge, IL
5Interventional Radiology, Lutheran General Hospital, Park Ridge, IL

*signifies non-member of ASH